SkinHealth Systems (SKIN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
31 Jul, 2026Executive summary
Special Meeting scheduled for September 22, 2026, to be held virtually for all stockholders of record as of August 3, 2026.
Two proposals up for vote: a reverse stock split amendment and potential adjournment if quorum or votes are insufficient.
Board recommends voting in favor of both proposals to maintain Nasdaq listing and provide flexibility.
Proxy materials are available online, with voting accessible by internet, phone, or mail.
Voting matters and shareholder proposals
Proposal 1: Approve an amendment for a reverse stock split of Class A Common Stock at a ratio between 1-for-5 and 1-for-20, ratio to be set by the board within one year.
Proposal 2: Approve adjournment of the meeting if more time is needed to solicit votes or establish a quorum.
Board unanimously recommends voting FOR both proposals.
Stockholders can submit proposals for the 2027 annual meeting by December 25, 2026, and must comply with SEC and bylaw requirements.
Board of directors and corporate governance
Board retains discretion to set the reverse split ratio and to abandon the split if deemed not in the best interest of stockholders.
Proxy solicitation may be assisted by a firm, with estimated fees up to $20,000 plus expenses.
Board members and executive officers have interests only as stockholders.
Latest events from SkinHealth Systems
- Q2 2026 sales fell 7.8%, but margins and liquidity improved; FY guidance lowered.SKIN
Q2 20266 Aug 2026 - Director elections, auditor ratification, and executive pay were addressed; no questions submitted.SKIN
AGM 202610 Jun 2026 - Adjusted EBITDA rose to $8.5M as sales fell and guidance was lowered amid market headwinds.SKIN
Q1 20268 May 2026 - Virtual annual meeting to vote on directors, auditor, and executive pay, with focus on governance and ESG.SKIN
Proxy filing24 Apr 2026 - Margins and profitability improved in 2025, with stable outlook and growth expected in 2027.SKIN
Q4 202525 Mar 2026 - Net sales dropped 22.9% as device sales lagged, prompting a downward revision to 2024 guidance.SKIN
Q2 20242 Feb 2026 - Gross margin rebounded to 51.6% in Q3 2024 despite a 19.1% sales decline.SKIN
Q3 202414 Jan 2026 - Gross margin and adjusted EBITDA improved despite lower sales and system placements.SKIN
Q4 202424 Dec 2025 - Annual meeting to vote on directors, auditor, and executive pay, with emphasis on governance and ESG.SKIN
Proxy Filing1 Dec 2025